In psycholytic therapy, threshold doses of hallucinogens (LSD-25, psilocybin, CZ-74, and CEY-19) activate unconscious conflict material in a way that is intensely experiential and meaningful for the patient. The drugs' chemical-pharmacological effects can be disregarded beyond their psychoactive role as an adjuvant to the depth-psychological or psychoanalytic process, making this an experimental psychoanalysis. The clinical technique—including patient attunement (set and setting), the type of psychodynamics released, and clinical and statistical results—is detailed, along with indications, contraindications, and risks such as hallucinogen misuse, activation of latent psychosis, and discussed effects on chromosomes.
Psilocybin, a psychedelic compound, shows promise in treating anxiety and depression among patients with gynecological cancers. In a study involving 50 participants, 80% reported reduced anxiety levels after psilocybin therapy, while 70% experienced significant improvements in mood. The effects were linked to changes in brain activity related to emotional regulation. Additionally, the chemical synthesis of psilocybin from natural alkaloids highlights its potential as a novel medicine, bridging molecular biology and drug studies for mental health treatment.